Interestingly, our proteomic analysis and previous metabolic profiling of ccRCC show evidence of late-stage tumors upregulating the OXPHOS pathway relative to earlier-stage tumors (Hakimi et al., 2016) and may reflect the dysregulation of HIF-1α expression resulting from 14q loss or the aberrant methylation profiles associated with CIMP+ status. This evidence concerns the gene HIF1A and nonpapillary renal cell carcinoma.